Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Current Assets
All assets expected to be converted to cash or used up within one year.
Helix BioPharma Corp.TSX: HBP.TO
Total Current Assets · Q3 FY2026 · quarter ended Apr 2026
Total current assets rises 198.6% from a year ago
Total current assets stood at CA$2.99M at the end of Q3 FY2026, up 198.6% from a year earlier and up 2116.3% from the prior quarter. Over 3 fiscal years it compounded at -52.0% a year.
Context
- Total current assets amounted to 14.0% of total assets at the end of Q3 FY2026, down 85.3 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +198.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
CAD · from the balance sheet
- Latest · FY2025
- 409K CAD
- Year-over-year change
- -71.9%
- 4-year CAGR
- -43.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 409K | -71.9% |
| FY2024 | 2024-07-31 | 1.46M | +46.2% |
| FY2023 | 2023-07-31 | 996K | -73.0% |
| FY2022 | 2022-07-31 | 3.7M | -8.0% |
| FY2021 | 2021-07-31 | 4.02M | — |
Total Current Assets vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +198.6% is the highest of 5, against a peer median of +4.4%.
- Total current assets amounts to 14.0% of total assets for HBP.TO, versus a peer median of 99.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $75.27M USD | +69.7% | +142.5% | 100.0% |
| Mar 2026 | CA$31.27M CAD | +23.7% | -27.4% | 99.6% | |
| Mar 2026 | $28.97M USD | -15.0% | -13.2% | 22.1% | |
| Apr 2026 | CA$2.99M CAD | +198.6% | -52.0% | 14.0% | |
| Apr 2026 | CA$1.53M CAD | -47.6% | -78.3% | 99.4% | |
| Peer median (excluding HBP.TO) | — | +4.4% | -20.3% | 99.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.